Clinical Factors Associated with Urinary Tract Cancer in Individuals with Lynch Syndrome
- 1 January 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 29 (1) , 193-199
Abstract
Background: Lynch syndrome confers markedly increased risks of various malignancies, including urinary tract cancers (UTC; renal pelvis, ureter, bladder, and possibly kidney cancers). It is unknown how to determine which Lynch syndrome carriers are at highest UTC risk. Our aim was to identify clinical factors associated with UTC among Lynch syndrome carriers. Methods: The study population was a cohort of 52,758 consecutively ascertained individuals undergoing Lynch syndrome testing at a commercial laboratory. Clinical data were obtained from test request forms completed by the ordering provider. Univariate analysis and multivariate logistic regression were performed to identify factors associated with UTC among Lynch syndrome carriers. Results: Compared with noncarriers, Lynch syndrome carriers were significantly more likely to have had UTC (4.1% vs. 1.2%; P < 0.0001). Lynch syndrome–associated UTC was independently associated with male sex [OR 1.95; 95% confidence interval (CI), 1.38–2.76], increased age (OR 2.44 per 10 years; 95% CI, 2.11–2.82), familial burden of UTC (OR 2.69 per first-/second-degree relative with UTC; 95% CI, 1.99–3.63), and pathogenic EPCAM/MSH2 variants (OR 4.01; 95% CI, 2.39–6.72) but not MLH1 variants (OR 1.17; 95% CI, 0.63–2.17), race, or history of other Lynch syndrome–associated malignancy. A total of 143 of 158 (90.5%) Lynch syndrome carriers with UTC had ≥1 of the following characteristics: male sex, EPCAM/MSH2 variants, or family history of UTC; 1,236 of 1,251 (98.8%) Lynch syndrome carriers lacking all of these characteristics had no history of UTC. Conclusions: Specific clinical factors can reliably identify Lynch syndrome carriers most likely to be at risk for UTC. Impact: A predictable subset of Lynch syndrome carriers may be most likely to benefit from UTC surveillance/prevention.Keywords
Funding Information
- HHS | NIH | National Cancer Institute (K24CA113433)
- HHS | NIH | National Cancer Institute (R01CA132829)
- HHS | NIH | National Cancer Institute (K07CA151769)
- The Pussycat Foundation Helen Gurley Brown Presidential Initiative
This publication has 32 references indexed in Scilit:
- Detection and Surveillance of Bladder Cancer Using Urine Tumor DNACancer Discovery, 2019
- Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-CancerJournal of Clinical Oncology, 2019
- Screening and surveillance in hereditary gastrointestinal cancers: Recommendations from the European Society of Digestive Oncology (ESDO) expert discussion at the 20th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona, June 2018European Journal of Cancer, 2018
- Cancer Risks for PMS2-Associated Lynch SyndromeJournal of Clinical Oncology, 2018
- Development and Validation of the PREMM5 Model for Comprehensive Risk Assessment of Lynch SyndromeJournal of Clinical Oncology, 2017
- Urinary Tract Cancer in Lynch Syndrome; Increased Risk in Carriers of MSH2 MutationsUrology, 2015
- Hereditary Colorectal Cancer Syndromes: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the Familial Risk–Colorectal Cancer: European Society for Medical Oncology Clinical Practice GuidelinesJournal of Clinical Oncology, 2015
- Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriersJournal of Medical Genetics, 2010
- Screening for urinary tract cancer with urine cytology in Lynch syndrome and familial colorectal cancerFamilial Cancer, 2008
- Prophylactic Surgery to Reduce the Risk of Gynecologic Cancers in the Lynch SyndromeNew England Journal of Medicine, 2006